Resectable Oral and Oropharyngeal Squamous Cell Carcinoma
2 clinical trials · Condition
◉ Watch Resectable Oral and Oropharyngeal Squamous Cell Carcinoma
| Record | Firm | Date |
|---|---|---|
| Neoadjuvant and Adjuvant Sintilimab Plus Cetuximab in Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma (NCT07079410) | Shanghai Zhongshan Hospital | 2025-07-01 |
| Preoperative Tislelizumab -Cetuximab - Chemotherapy Followed by Salvage Surgery and Adjuvant Tislelizumab -Cetuximab for Resectable, Locally Recurrent Oral and Oropharyngeal Squamous Cell Carcinoma (NCT06728618) | Shanghai Zhongshan Hospital | 2024-12-01 |
Track Resectable Oral and Oropharyngeal Squamous Cell Carcinoma automatically
Every clearance here is in the API, with alerts when new ones post.